Mitigating Paxlovid™-induced drug‒drug interaction toxicity: an in silico insight

The clinical drug-drug interaction side-effects of Ritonavir, an ingredient in Paxlovid™, have been documented, highlighting the need to explore alternative administration methods for Nirmatrelvir, another drug in the Paxlovid™ combination. In this study, the skin permeability potential of Nirmatrel...

Full description

Bibliographic Details
Published in:Frontiers in Pharmacology
Main Authors: Giang H. Ta, Max K. Leong
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-11-01
Subjects:
in silico
skin permeability
Paxlovid
nirmatrelvir
COVID-19
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1496630/full
Description
Summary:The clinical drug-drug interaction side-effects of Ritonavir, an ingredient in Paxlovid™, have been documented, highlighting the need to explore alternative administration methods for Nirmatrelvir, another drug in the Paxlovid™ combination. In this study, the skin permeability potential of Nirmatrelvir was assessed using various in silico models. The prediction results suggest that Nirmatrelvir could be administrated via the transdermal route, offering a promising avenue to enhance the efficacy of anti-COVID-19 agents.
ISSN:1663-9812

Similar Items